5,954 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Truepoint Inc.

Truepoint Inc. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,954 shares of the company's stock, valued at approximately $413,000.

Other large investors have also added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL grew its holdings in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new stake in Novo Nordisk A/S during the first quarter worth about $27,000. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $29,000. Finally, Transce3nd LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $33,000. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on NVO shares. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $93.67.

Novo Nordisk A/S Price Performance

NVO stock opened at $48.76 on Friday. The company has a market capitalization of $217.73 billion, a P/E ratio of 13.40, a PEG ratio of 1.37 and a beta of 0.63. The company has a fifty day moving average price of $67.55 and a 200-day moving average price of $71.81. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 84.92% and a net margin of 35.60%. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 45.05%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.